Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 19/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21869517 | 1.00 | SLC10A1 (0.51) | SLC10A1PTGS1PTGS2 | |
| SCHEMBL22646298 | 0.98 | SLC10A1 (0.50) | SLC10A1PTGS1PTGS2 | |
| SCHEMBL21869307 | 0.97 | SLC10A1 (0.49) | SLC10A1PTGS1PTGS2 | |
| SCHEMBL22646484 | 0.97 | SLC10A1 (0.49) | SLC10A1PTGS1PTGS2 | |
| SCHEMBL22646453 | 0.97 | SLC10A1 (0.49) | SLC10A1PTGS1PTGS2 | |
| SCHEMBL21868862 | 0.93 | SLC10A1 (0.51) | SLC10A1PTGS1PTGS2 | |
| SCHEMBL22646380 | 0.91 | SLC10A1 (0.54) | SLC10A1 | |
| SCHEMBL21869120 | 0.90 | SLC10A1 (0.55) | SLC10A1 | |
| SCHEMBL22646456 | 0.89 | SLC10A1 (0.53) | SLC10A1 | |
| SCHEMBL21869066 | 0.89 | SLC10A1 (0.48) | SLC10A1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SLC10A1, NUP188, NR1H4 | SLC10A1 1/4885PTGS1 970/4885PTGS2 2334/4885 |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SLC10A1, NR1H4, NUP188 | SLC10A1 1/4885PTGS1 2835/4885PTGS2 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.